Baird Financial Group Inc. Buys New Holdings in Takeda Pharmaceutical Co. $TAK

Key Points

• Baird Financial Group Inc. has invested $276,000 in Takeda Pharmaceutical Co., purchasing 18,583 shares during the first quarter.
• Takeda Pharmaceutical reported earnings of $0.52 per share, exceeding analyst expectations of $0.47, but its revenue of $7.45 billion fell short of the projected $7.96 billion.
• Recent analyst ratings show that Takeda's stock has been downgraded to a "strong sell" by Zacks Research, although the average rating remains a "hold."

Baird Financial Group Inc. acquired a new position in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 18,583 shares of the company's stock, valued at approximately $276,000.

Other hedge funds also recently added to or reduced their stakes in the company. FNY Investment Advisers LLC bought a new position in Takeda Pharmaceutical in the first quarter worth about $37,000. Farther Finance Advisors LLC raised its holdings in Takeda Pharmaceutical by 29.2% in the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock worth $69,000 after purchasing an additional 1,045 shares in the last quarter. Fifth Third Bancorp raised its holdings in Takeda Pharmaceutical by 85.5% in the first quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock worth $78,000 after purchasing an additional 2,411 shares in the last quarter. Point72 Hong Kong Ltd bought a new position in Takeda Pharmaceutical in the fourth quarter worth about $94,000. Finally, GAMMA Investing LLC raised its holdings in Takeda Pharmaceutical by 22.6% in the first quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock worth $105,000 after purchasing an additional 1,296 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Down 0.2%

Shares of TAK traded down $0.03 during mid-day trading on Wednesday, hitting $15.10. 3,494,229 shares of the company traded hands, compared to its average volume of 2,957,714. Takeda Pharmaceutical Co. has a 1-year low of $12.80 and a 1-year high of $15.69. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $48.03 billion, a PE ratio of 50.32 and a beta of 0.22. The business has a 50 day moving average of $14.81 and a 200 day moving average of $14.84.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The firm had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Equities research analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded shares of Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a report on Thursday, August 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Takeda Pharmaceutical has an average rating of "Hold".

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.